Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma

Cheng, 2012

Kouba, 2016, Neuroendocrine tumors of the urinary bladder according to the 2016 World Health Organization classification: molecular and clinical characteristics, Endocr Pathol, 27, 188, 10.1007/s12022-016-9444-5

Blomjous, 1989, Small cell carcinoma of the urinary bladder. a clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases, Cancer, 64, 1347, 10.1002/1097-0142(19890915)64:6<1347::AID-CNCR2820640629>3.0.CO;2-Q

Cheng, 2005, Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma, Am J Pathol, 166, 1533, 10.1016/S0002-9440(10)62369-3

Allory, 2014, Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome, Eur Urol, 65, 360, 10.1016/j.eururo.2013.08.052

Barthel, 2017, Systematic analysis of telomere length and somatic alterations in 31 cancer types, Nat Genet, 49, 349, 10.1038/ng.3781

Bell, 2016, Understanding T.E.R.T. promoter mutations: a common path to immortality, Mol Cancer Res, 14, 315, 10.1158/1541-7786.MCR-16-0003

Borah, 2015, Cancer: TERT promoter mutations and telomerase reactivation in urothelial cancer, Science, 347, 1006, 10.1126/science.1260200

Hurst, 2014, Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine, Eur Urol, 65, 367, 10.1016/j.eururo.2013.08.057

Kouba E, Cheng L. Understanding the genetic landscape of small cell carcinoma of the urinary bladder and implications for diagnosis, prognosis and treatment. JAMA Oncol. In press.

Liu, 2013, Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma, Cell Cycle, 12, 1637, 10.4161/cc.24662

Vinagre, 2014, Telomerase promoter mutations in cancer: an emerging molecular biomarker?, Virchows Arch, 465, 119, 10.1007/s00428-014-1608-4

Huang, 2013, Highly recurrent TERT promoter mutations in human melanoma, Science, 339, 957, 10.1126/science.1229259

Cheng, 2015, Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites, Ann Diagn Pathol, 19, 146, 10.1016/j.anndiagpath.2015.03.005

Cowan, 2016, High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder, Mod Pathol, 29, 511, 10.1038/modpathol.2016.53

Cowan, 2016, Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder, Hum Pathol, 53, 8, 10.1016/j.humpath.2016.02.009

Cheng, 2017, TERT promoter mutations occur frequently in urothelial papilloma and papillary urothelial neoplasm of low malignant potential, Eur Urol, 71, 497, 10.1016/j.eururo.2016.12.008

Cheng, 2016, Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change, Histopathology, 69, 107, 10.1111/his.12920

Moch, 2016

Cheng, 2013, Laser-assisted microdissection in translational research: theory, technical considerations, and future applications, Appl Immunohistochem Mol Morphol, 21, 31, 10.1097/PAI.0b013e31824d0519

Wang, 2017, TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract, Future Oncol, 13, 705, 10.2217/fon-2016-0414

Kim, 2004, Extrapulmonary small-cell carcinoma: a single-institution experience, Jpn Clin Oncol, 34, 250, 10.1093/jjco/hyh052

Ochsenreither, 2009, Extrapulmonary small cell carcinoma (EPSCC): 10 years’ multi-disciplinary experience at Charité, Anticancer Res, 29, 3411

Sengoz, 2003, Extrapulmonary small cell carcinoma: multimodality treatment results, Tumori, 89, 274, 10.1177/030089160308900308

Cancer Genome Atlas Research Network, 2014, Comprehensive molecular characterization of urothelial bladder carcinoma, Nature, 507, 315, 10.1038/nature12965

Kim, 2015, Invasive bladder cancer: Genomic insights and therapeutic promise, Clin Cancer Res, 21, 4514, 10.1158/1078-0432.CCR-14-1215

Pan, 2005, c-kit expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications, Mod Pathol, 18, 320, 10.1038/modpathol.3800318

Wang, 2005, P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications, Anticancer Res, 25, 2001

Soriano, 2004, Small-cell carcinoma of the urinary bladder: A clinico-pathological study of ten cases, Virchows Arch, 445, 292, 10.1007/s00428-004-1041-1

Wang, 2007, Small cell carcinoma of the urinary bladder–histogenesis, genetics, diagnosis, biomarkers, treatment, and prognosis, Appl Immunohistochem Mol Morphol, 15, 8, 10.1097/01.pai.0000213106.12731.d7

Zheng, 2014, High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins, J Hematol Oncol, 7, 47, 10.1186/s13045-014-0047-7

Gaisa, 2008, Insights from a whole cystectomy specimen—association of primary small cell carcinoma of the bladder with transitional cell carcinoma in situ, Hum Pathol, 39, 1258, 10.1016/j.humpath.2007.12.017

Andor, 2016, Pan-cancer analysis of the extent and consequences of intratumor heterogeneity, Nat Med, 22, 105, 10.1038/nm.3984

Sung, 2007, Histogenesis of sarcomatoid urothelial carcinoma of the urinary bladder: evidence for a common clonal origin with divergent differentiation, J Pathol, 211, 420, 10.1002/path.2129

Cheng, 2011, Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation, Am J Surg Pathol, 35, e34, 10.1097/PAS.0b013e3182159dec

Van Batavia, 2014, Bladder cancers arise from distinct urothelial sub-populations, Nat Cell Biol, 16, 982, 10.1038/ncb3038

Davis, 1983, Small cell neuroendocrine carcinoma of the urinary bladder: report of three cases with ultrastructural analysis, Ultrastruct Pathol, 4, 197, 10.3109/01913128309140790

Cheng, 2004, Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients, Cancer, 101, 957, 10.1002/cncr.20456

Cheng, 2011, Bladder cancer: translating molecular genetic insights into clinical practice, Hum Pathol, 42, 455, 10.1016/j.humpath.2010.07.007

Monn, 2016, Emerging trends in the evaluation and management of small cell prostate cancer: A clinical and molecular perspective, Expert Rev Anticancer Ther, 16, 1029, 10.1080/14737140.2016.1226137

Andreoiu, 2010, Multifocal prostate cancer: biological, prognostic, and therapeutic implications, Hum Pathol, 41, 781, 10.1016/j.humpath.2010.02.011

Schelling, 2013, Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry, Hum Pathol, 44, 2227, 10.1016/j.humpath.2013.05.005

Williamson, 2011, ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin, Mod Pathol, 24, 1120, 10.1038/modpathol.2011.56

Liu, 2014, Diagnostic accuracy of high resolution melting analysis for detection of KRAS mutations: a systematic review and meta-analysis, Sci Rep, 4, 7521, 10.1038/srep07521